hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo
Version of Record online: 10 OCT 2001
Copyright © 2001 Wiley-Liss, Inc.
Volume 31, Issue 2, pages 85–94, October 2001
How to Cite
Zhuo, L., Theis, M., Alvarez-Maya, I., Brenner, M., Willecke, K. and Messing, A. (2001), hGFAP-cre transgenic mice for manipulation of glial and neuronal function in vivo. Genesis, 31: 85–94. doi: 10.1002/gene.10008
- Issue online: 10 OCT 2001
- Version of Record online: 10 OCT 2001
- Manuscript Accepted: 28 AUG 2001
- Manuscript Received: 23 JUL 2001
- National Institutes of Health. Grant Numbers: NS-39055, NS-22475
- Lie Foundation
- German Research Association. Grant Number: SFB 400, B3
- central nervous system;
- gene targeting
With the goal of performing astrocyte-specific modification of genes in the mouse, we have generated a transgenic line expressing Cre recombinase under the control of the human glial fibrillary acidic protein (hGFAP) promoter. Activity was monitored by crossing the hGFAP-cre transgenics with either of two reporter lines carrying a lacZ gene whose expression requires excision of loxP-flanked stop sequences. We found that lacZ expression was primarily limited to the central nervous system, but therein was widespread in neurons and ependyma. Cell types within the brain that notably failed to activate lacZ expression included Purkinje neurons of the cerebellum and choroid plexus epithelium. Onset of Cre expression began in the forebrain by e13.5, suggesting that the hGFAP promoter is active in a multi-potential neural stem cell. genesis 31:85–94, 2001. © 2001 Wiley-Liss, Inc.